Glutethimide is a hypnotic sedative drug which is a safe alternative to barbiturates for treatment of insomnia. It mainly used for patients to feel sleepy and make them calm. Glutethimide is highly lipophilic and concentrates in adipose tissue and brain. It is an alternative for barbiturates. It undergoes extensive metabolism in liver with both unconjugated and conjugated metabolites which kidney excretes. Glutethimide is a CYP2D6 enzyme inducer and when it taken with codeine, it enables the body to convert high amount of codeine to morphine. The most common brand name for glutethimide are ciba, glue, and gofers. It is categorized as schedule II drug under psychotropic substances. Moreover, glutethimide is used to prevent jaundice in newborns and reduce muscle tremors.
COVID-19 Impact analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. This highly contagious disease, caused by a virus, is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)that is transmitted from one person to another. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a pandemic on March 11, 2020.
Pharmaceutical and biotech companies together with governments all across the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the glutethimide market.
Top Impacting Factors
- Increase in cases of cardiovascular depression, rise in demand to maintain calmness and induce sleep, increase in cases of mental illness, rise in demand for treatment of psychiatric patient to reduce tension, rise in demand for the brands such as doriden, elrodorm, glimid, rise in development of new analgesic drugs, increase in availability of drugs such as butisol, ambien, restoril, zolpimist, and increase in seizure disorders are factors that drive the growth of glutethimide market
- In addition, increase in healthcare expenditure; availability of skilled professionals; collaborations & partnerships between key players to facilitate drug development; rise in R&D activities to improve quality of drugs; launch of novel developed drug in market; and technological development such as computer technology, aseptic spray drying, 3 D printing to manufacture a drug which boost the market growth for glutethimide market.
- However, side effects associated with glutethimide and drug shortage hinder the market growth.
- Contrarily, increase in awareness regarding treatment of insomnia and government initiatives for regulatory approvals are expected to offer lucrative opportunities for the expansion of the glutethimide market.
Market Trends
Rise in R & D activities to flourish the market
- A study of 70 patients had completed the treatment of acute glutethimide intoxication a Doriden without use of hemodialysis in Rhode Island hospital.
- Gross Tripod and Meier had examined some pharmacological action of glutethimide in obstertrics at southmead hospital in Bristol. It had anticonvulsive properties. A study of 60 patients shown a satisfactory result of 1.0 mg of glutethimide (doriden) at bedtime and 1.0 g. one- and one-half hours before.
- The University of Medicine and Pharmacy in Romania has investigated effect of glutethimide on brain of rat by sub-chronic codeine treatment. The guanine and adenine nucleotides in rat brain were assayed by using high performance liquid chromatography.
Key Benefits of the Report
- This study presents the analytical depiction of the glutethimide industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the share.
- The current market is quantitatively analyzed to highlight glutethimide market growth scenario.
- Porter’s Five Forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed glutethimide market analysis based on competitive intensity and the competition that will take shape in coming years
Questions Answered in the Glutethimide Report
- Who are the leading market players active in the glutethimide market?
- What current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the glutethimide market?
- What future projections would help in taking further strategic steps for glutethimide?
- What is " glutethimide "?
- What is “glutethimide " Market prediction in the future?
- Who are the leading global players in the “glutethimide “Market?
- What are the current trends and predicted trends of glutethimide market?
- What are the key benefits of the "glutethimide" Market report?
Glutethimide Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Agilent Technologies, Abbvie Inc, Astrazeneca, Sanofi S.A, Pfizer Inc., Novartis, Mankind Pharma, Abbott Laboratories, Glaxosimithkine PLC, Bristol Mayers Squibb |
Loading Table Of Content...
